Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension

Arquivos Brasileiros de Cardiologia

Volumn 104, Issue 1, 2015, Pages 85-89

  de Faria, Ana Paula Cabral ^a   Modolo, Rodrigo ^a   Moreno, Beatriz Vaz Domingues ^a   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Heart failure; Hypertension; Left ventricular dysfunction; Phosphodiesterase 5 inhibitors therapeutic use; Vasodilator agents therapeutic use

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE 32; CYCLIC GMP; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFECT; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; HEART FAILURE; HEART PALPITATION; HEMODYNAMIC PARAMETERS; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; NONHUMAN; PREVALENCE; RESISTANT HYPERTENSION; REVIEW; SHORT COURSE THERAPY; DIASTOLE; DRUG EFFECTS; DRUG RESISTANCE; HEART FAILURE, DIASTOLIC; HEART LEFT VENTRICLE FUNCTION; HYPERTENSION; MEDICAL ILLUSTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

CARBOLINES; DIASTOLE; DRUG RESISTANCE; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; MEDICAL ILLUSTRATION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SILDENAFIL CITRATE; SULFONAMIDES; TADALAFIL; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84923620742     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20140159     Document Type: Review

References (36)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-19.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80.
3. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125(13):1594-6.
4. Faria AP, Sabbatini AR, Coca A, Moreno H. Phenotypic characteristics of resistant hypertension in the Brazilian population. Arq Bras Cardiol. 2013;100(6):579-82.
5. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, et al. Aldosterone excess or escape: Treating resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(5):245-52.
6. Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension. 1993;22(3):380-7.
7. Pechanova O, Bernatova I, Pelouch V, Babal P. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res. 1999;48(5):353-62.
8. Ferreira-Melo SE, Yugar-Toledo JC, Coelho OR, De Luca IM, Tanus-Santos JE, Hyslop S, et al. Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol. 2006;542(1-3):141-7.
9. Ferreira-Melo SE, Demacq C, Lacchini S, Krieger JE, Irigoyen MC, Moreno H. Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles. Clinics (Sao Paulo). 2011;66(7):1253-8.
10. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369(9579):2079-87.
11. Quinaglia T, de Faria AP, Fontana V, Barbaro NR, Sabbatini AR, Sertorio JT, et al. Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. Eur J Clin Pharmacol. 2013;69(12):2027-36.
12. Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos- Souza JR, et al. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014;70(2):147-54.
13. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48(4):622-7.
14. Oliver JJ, Hughes VE, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension. 2010;56(1):62-67. Erratum in: Hypertension. 2012;60(1):e8.
15. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83(5):13C-20C.
16. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1:5-12.
17. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res. 1999;43(2):344-53.
18. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22(1):318-25.
19. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005;112(17):2642-9.
20. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525-63.
21. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des. 2006;12(27):3485-94.
22. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214-22.
23. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007;101(11):1084-95.
24. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011;124(25):2882-91.
25. Westermann D, Becher PM, Lindner D, Savvatis K, Xia Y, Frohlich M, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II- induced heart failure in vivo. Basic Res Cardiol. 2012;107(6):308.
26. Parekh N, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol. 2009;24(2):155-60.
27. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol. 2004;43(1):55-60.
28. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparisonwith Doppler velocity recordings. Circulation. 2002;105(5):595-601.
29. Grewal J, McKelvie R, Lonn E, Tait P, Carlsson J, Gianni M, et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail. 2008;10(3):252-9.
30. Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich). 2011;13(7):523-8.
31. Williams B. Resistant hypertension: an unmet treatment need. Lancet. 2009;374(9699):1396-8.
32. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194-202.
33. Rivas-Gotz C, Khoury DS, Manolios M, Rao L, Kopelen HA, Nagueh SF. Time interval between onset of mitral inflow and onset of early diastolic velocity by tissue Doppler: a novel index of left ventricular relaxation: experimental studies and clinical application. J Am Coll Cardiol. 2003;42(8):1463-70.
34. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8-17.
35. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):1422-8.
36. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar- Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify “true” resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(4):183-91.